Program

1st Day Program         2nd Day Program

December 3, 2009


08:45-09:00 Welcome Address by the Ambassador
of France H.E. Pierre Vimont
09:00-09:20 Introduction and Welcome
Prof Fabien CALVO, MD, PhD
Deputy Director at the French National Cancer
Institute (INCA), Director of the Multi-Institutions Institute, thematic “Cancer”, French National Institute
of Medical Research (INSERM)
09:20-09:40 Introduction and Welcome
Prof Mauro FERRARI
Professor and Chairman,
Department of Nanomedicine
and Biomedical Engineering (nBME)
Professor of Internal Medicine, Division
of Cardiology, The University of Texas Health Science Center
09:40-10:10 Elizabeth Mansfield, PhD
Senior Genomoics Advisor
Office of the Chief Scientist
U.S. Food and Drug Administration

Lecture: FDA's perspective relative
to the Validation of biomarkers

(to be confirmed)

>>> Questions and answers

10:15-10:45

Dr Susan Windham-Bannister, PhD
President and CEO Massachusetts Life Sciences Center

lecture: Will be last minute determined

>>> Questions and answers
10:50-11:00 COFFEE BREAK
11:00-11:30 Prof Pierre LAURENT-PUIG, MD, PhD
Professor at the Paris Descartes University Medical School

Lecture: Biomarkers of Response
to Anti EGFR Therapy in Colorectal Cancer


>>> Questions and answers
11:35-12:05 Prof Naomi J. HALAS, PhD
Professor, Department of Physics and
Astronomy, Department of Biomedical
Engineering, Department of Chemistry,
Rice University, Houston, TX, USA
Director, Laboratory for Nanophotonics, Rice University, Houston, TX, USA
Stanley C. Moore Professor in Electrical and Computer Engineering, Rice University, Houston, TX, USA

Lecture: Light-based nanomedicine
for cancer: merging diagnostics and drug-free therapeutics


>>> Questions and answers
12:10-12:40 Dr Pierre CHAURAND, PhD
Associate Professor, VICC Member
Vanderbilt University Medical Center

Lecture: Imaging mass spectrometry: state of the technology and clinical potentials

>>> Questions and answers
12:45-14:00 LUNCH
14:00-14:30 Prof Jessica ZUCMAN, MD, PhD
Professor of Medicine, Oncology, University Paris Descartes, Hopital Européen Georges Pompidou, Head of the INSERM laboratory, “Functional genomic of solid tumors” in Paris

Lecture: Molecular classification
of Hepatocarcinoma (HCC): new insights and interest in clinical practice


>>> Questions and answers
14:35-15:05 Dr Franck PEREZ, PhD
Research Director at CNRS in France
Group leader in the Cell Biology Section
at the Curie Institute (Paris, France)

Lecture: Conformation-specific antibodies
selected by an antibody phage display approach


>>> Questions and answers
15:10-15:40 Prof Bernard BIHAIN, MD
Chairman of GENCLIS

Lecture: Increased transcription infidelity
in cancer cells deregulates innate humoral
immunity and provides  novel method for early stage  diagnosis


>>> Questions and answers
15:45-16:00 COFFEE BREAK
16:00-16:30 Prof Ralph BRADSHAW, PhD
Professor, Department of Pharmaceutical
Chemistry, University of California (UCSF), San Francisco, CA, and Deputy Director, Mass Spectrometry Facility, UCSF, San Francisco, CA

lecture: Will be last minute determined

>>> Questions and answers
16:35-17:05 Prof Gilles THOMAS, MD, PhD
Fondation Synergie-Lyon-Cancer
Professor of Medical Genetics at University LYON 1

Lecture: Genome wide association studies for cancer predisposition

>>> Questions and answers
17:10-17:40 Dr François BERGER, MD, PhD
Head of the Cell Biology Department
in Joseph Fourier University Medical School
Head of the “Brain Nanomedicine” group in the INSERM, Research Center U 836 (ex U 318), Head of the clinico-biologal Neuro-oncology unit in Grenoble university hospital

lecture: A Theranostic micro-nanotechnology strategy opening the exploration of « tissue-poly-omic » inaccessible territories

>>> Questions and answers
17:45 CONCLUSION



















































































Top of Page

December 4, 2009


07:30-07:45 Registration and breakfast
07:45-08:00 Presentation of Mérieux Alliance
and its strategy for innovation
by Christian Bréchot, Vice-president
of scientific and medical affairs
08:00-08:15 Presentation of Mérieux Développement, private equity firm by
François Valencony, Managing director
08:15-08:25

Daniel Wang, Oranoxis Inc.

Oral Fluid Taesting for Therapeutic Cancer Drug Monitoring

08:25-08:35

Benjamin A. Belinka, Actinobac Biomed, Inc.

Leukotoxin for the Diagnosis and Treatment of Autoimmune Diseases

08:35-08:45

David T. Wong, UCLA School of Dentistry

Salivary Diagnostics for Molecular Oncology Applications

08:45-08:55

Virginie Clément, University Hospital of Geneva

An effort to enhance the development of biomarkers for brain tumors using a unique technology developed by our laboratory and Stemergie

08:55-09:05

Matthew Gombrich, Viridis Diagnostics

A Novel Rapid Theranostic Test for Severe Bacterial Pneumonia – Moving Theranostics into the Acute Care Setting to Reduce Broad Spectrum Prescribing of Antibiotics

09:05-09:15

Frederic Bienvenu, Dana-Farber Cancer Institute

Transcription-Nuclear Export Coupling as a New Cancer Diagnosis-Prognosis and Therapeutic Target

09:15-09:25

Victor V Levenson, Rush U Medical Center

DNA methylation patterns of antiestrogen-resistant breast cancer

09:25-09:35

Fiorenzo Omenetto, Tufts University

A new green/sustainable platform for global delivery of medical and pharmaceutical products based on silk

09:35-09:45

Carol A. Kumamoto, Tufts University

Novel diagnostics for invasive candidiasis

09:45-09:55

Cavigiolio Giorgio, Children’s Hospital Oakland Research Institute

A New Biomarker of HDL Functionality for Cardiovascular Disease Risk Assessment

09:55-10:05

Christophe Egles, Tufts University

High throughput human tissue-equivalent platforms: new research tools for translational discovery and development

10:05-10:45 Coffee break and discussions around candidates’Posters
10:45-10:55

M. Philip N Tsichlis, Tufts Medical Center

The diagnostic and therapeutic applications of the imbalance between Akt1 and Akt2 in human Cancer

10:55-11:05

Joel Berniac / Ban-An Khaw, Akrivis Technologies LLC Akrivis Technologies LLC

Development and Applications of Novel Ultrasensitive Diagnostics and Targeted Therapeutics for the Early Detection and Treatment of Cancer.

11:05-11:15

Nancy Hurtado-Ziola / Mark Hattendorf, Gc-Free, Inc.

Dietary Red Meat, Neu5Gc and Inflammation:  Diagnosing Risk and Recommending Therapy

11:15-11:25

Pascal Puchois, Trans-Hit Biomarkers

A unique and highly efficient validation platform to accelerate the development of diagnostic biomarkers and theranostics in infectiology

11:25-11:35

Thomas Gauthier, Philips Ultrasound R&D

Novel non-invasive imaging biomarkers for cardiovascular disease and oncology

11:35-11:45

Al Tofighi, ETEX Corporation

New Class of nano-crystalline Combination Biomaterial for Minimally Invasive Treatment of Vertebral Compression Fractures.

11:45-11:55

David N. Ku / Larry J. Anderson, Emory School of Medicine

A New Pneumonia Theranostic Device – PneumoniaCheck

11:55-12:05

Catherine A. McCarty, Marshfield Clinic Research Foundation

Pharmacogenetics of beta blockers and prostanoid analogues in glaucoma

12:05-12:15

Fabien Campagne, Weill Medical College of Cornell University

Commercial Platform for Dependable Predictive Model Development and Evaluation

12:15-12:25

Alex Turjman

Why and when aneurysms form and grow

12:25-12:35

Robert K. Prud’homme / Robert H. Austin, Princeton University

New generation of imaging and labeling agents based on nanocrystalline Upconversion Phosphors (UCP)

12:35-12:45

Amit Banerjee, College of Pharmacy, Wayne State University

Protein Ubiquitination Enzymes as Theranostics Targets for your call: "Theranostics and Biology: Know-How Challenges, Applications & Breakthroughs”

12:45-12:55

Peter Libby, Brigham and Women's Hospital

Theranostic nanotechnology approach to treating atherosclerotic plaques
12:55-14:30 Cocktail and lunch


Top of Page